Another day at the money makin’ factory …
^
Exclusively using SPM+Game Theory PRO the success ratings was 80%, representing 8 out of 10 suggestions were correct with a 24-hour full cycle trading time limit.
$EQIX, $EXR, $LRCX, $ARRS, $LOGI, $OI, $ORLY, $PSSI
| EQIX100821C00090000 | Sell | ![]() |
3.50 | 2010-Jul-27 15:43:05 | 3.90 | 2010-Jul-29 09:53:06 | 0.40 |
| EQIX100821C00090000 | Sell Call Option | ![]() |
2.04 | 2010-Jul-28 15:36:07 | 3.90 | 2010-Jul-29 09:52:21 | 1.86 |
| EXR | Sell | ![]() |
15.39 | 2010-Jul-28 15:54:34 | 15.66 | 2010-Jul-29 09:45:38 | 0.27 |
| EQIX | Sell | ![]() |
87.89 | 2010-Jul-28 15:30:14 | 92.41 | 2010-Jul-29 09:43:53 | 4.52 |
| LRCX | Sell | ![]() |
41.72 | 2010-Jul-28 15:55:12 | 42.99 | 2010-Jul-29 09:41:36 | 1.27 |
| ARRS | Sell | ![]() |
11.46 | 2010-Jul-28 15:56:15 | 10.35 | 2010-Jul-29 09:38:14 | -1.11 |
| OI | Sell | ![]() |
29.65 | 2010-Jul-28 15:56:54 | 30.00 | 2010-Jul-29 09:35:47 | 0.35 |
| PSSI | Sell | ![]() |
18.24 | 2010-Jul-28 15:59:09 | 18.35 | 2010-Jul-29 09:35:01 | 0.11 |
| ORLY | Sell | ![]() |
49.41 | 2010-Jul-28 15:57:36 | 49.39 | 2010-Jul-29 09:33:48 | -0.02 |
| LOGI | Sell | ![]() |
15.35 | 2010-Jul-28 16:00:51 | 16.51 | 2010-Jul-29 09:32:23 | 1.16 |
8:10 am … LRCX – Retain Long Position: Other views —
- Stifel Nicolaus raises price tgt to $56 from $51 noting that more credit is deserved for sustained performance. While firm anticipated a strong qtr driven by current market trends, believes the strong upside (and outlook) was driven by share gains in both its core etch and wet clean biz. Firm feels etch share wins in prior yrs are now turning into volume orders and shipments. Reits Buy rating and raises tgt to $56 reflecting a very conservative 10x new FY11 pro forma EPS est of $5.65, including options.
- Caris & Co notes that LRCX delivered a strong beat and guidance crushed expectations. Firm believes the strong guidance and positive comments bode well for earnings over the next several qtrs which should outweigh some of the near term demand concerns for electronics. Although investors may be concerned about the sustainability of earnings, LRCX remains one of firm’s top picks due to market share gains and leverage to NAND Flash spending and would be buying on any weakness. Firm’s FY11 ests go to $3.24B/$5.67 from $2.54B/$3.59. Introduces FY12 ests of $3.43B/$6.11. Price tgt goes to $52 from $48 (or 9x times firm’s new CY11 ests).
8:05 am … LRCX- Retain Long Position: LRCX gave a first-quarter outlook that far exceeded Wall Street expectations, on continued strong demand and market-share gains in its etch and clean product markets; forecast first-quarter earnings of $1.35, plus or minus 7 cents, per share, before items, on revenue of $790 million, give or take $15 million. Analysts on average were looking for earnings of 98 cents a share, before items, on revenue of $669.7 million.
8:04 am … EXR-Retain Long Position: Total revenues for the three months ended June 30, 2010 were $68.8 million compared to $69.1 million for the three months ended June 30, 2009. Total expenses for the three months ended June 30, 2010 were $46.0 million compared to $66.7 million for the three months ended June 30, 2009. Interest expense, including non-cash interest charges relating to the Company’s exchangeable senior notes, was $16.6 million compared to $16.4 million for the three months ended June 30, 2009. Net income for the three months ended June 30, 2010 was $7.9 million compared to a net loss of $6.7 million for the three months ended June 30, 2009. The net loss in the second quarter of 2009 was due to a $20.2 million charge associated with severance and impairment charges related to the Company’s decision to wind down its development program. For the three months ended June 30, 2010, the Company’s top performing markets in terms of revenue growth were Baltimore/Washington D.C., Chicago, Dallas, Denver, New York City and New England. Markets performing below the Company’s portfolio average in revenue growth included Atlanta, Las Vegas, Los Angeles, Miami, Phoenix and Tampa.Total revenues for the six months ended June 30, 2010 were $136.4 million compared to $138.3 million for the six months ended June 30, 2009. Total expenses for the three months ended June 30, 2010 were $92.7 million compared to $114.0 million for the six months ended June 30, 2009. Interest expense, including non-cash interest charges relating to the Company’s exchangeable senior notes, was $34.3 million compared to $33.0 million for the six months ended June 30, 2009. Net income for the six months ended June 30, 2010 was $13.1 million compared to $24.1 million for the six months ended June 30, 2009.
8:00 am … ORLY- Retain Long Position: Net income was $99.6 million, or 71 cents per share, in the second quarter, up from $85.5 million, or 62 cents per share, a year earlier. ORLY earned 81 cents per share on an adjusted basis, which excludes a charge of $15 million for estimated costs set aside to resolve an investigation undertaken by the Department of Justice. Analysts on average were expecting earnings of 74 cents per share. Sales rose 10 percent to $1.38 billion, as comparable-store sales rose nearly 8 percent. Analysts expected $1.35 billion. O’Reilly said it expects earnings of 69 cents to 73 cents per share for the third quarter and $2.64 to $2.74 for the full year. On an adjusted basis, the company expects to earn between $2.75 and $2.85 for the full year. Analysts were expecting earnings of 72 cents per share for the third quarter and $2.77 per share for the full year
7:52 am … LOGI – Retain Long Position: Reports Q1 (Jun) earnings of $0.11 per share, $0.08 better than the Thomson Reuters consensus of $0.03; revenues rose 46.9% year/year to $479 mln vs the $456.5 mln consensus. Co issues in-line guidance for FY11, sees FY11 revs of $2.3-2.35 bln vs. $2.32 bln Thomson Reuters consensus.
6:44 am … OI – SELL into any rally: Second-quarter net income fell to $141.1 million, or 85 cents a share, from $149.3 million, or 88 cents a share, a year ago. Excluding one-time items, the company would have reported earnings of 90 cents a share in the latest quarter. Analysts estimated earnings of 93 cents a share on revenue of $1.82 billion.
6:30 am … EQIX – Retain Long Position: Oppenheimer upgrades EQIX to Outperform from Perform and sets target price at $115 based on a more constructive stance on EQIX shares predicated on improving visibility into 2H10/2011 growth trajectory with close of SDXC acquisition; faster-than-expected realization of synergy benefits, generating margin expansion in 4Q10 and beyond; and increased scale leaves EQIX in a dominant market position and should aid pricing power.
6:00 am … ARRS – SELL Long Position into any rally: Posted lower-than-expected quarterly results and forecast a weak third quarter, and forecast third-quarter earnings of 16 cents a share to 20 cents a share, excluding items, on revenue of $270 million to $290 million. Analysts were looking for third-quarter earnings of 27 cents a share, before items, on revenue of $300.5 million. For the second quarter, the company earned $19.8 million, or 15 cents per share, compared with $22.9 million, or 18 cents a share. Excluding items, Arris earned 24 cents a share, slightly below analysts’ expectations of 25 cents a share.
4:54 am ... PSSI- Retain Long Position: Net sales for the three months ended July 2, 2010, were $478.9 million, a decrease of 3.0%, compared with net sales of $493.6 million for the three months ended June 26, 2009. Net sales for the three months ended July 2, 2010, for the Physician Business decreased by 4.3% (1.8% decrease excluding H1N1-related product sales in last year’s first quarter) and increased by 0.5% for the Elder Care Business. Income from operations for the three months ended July 2, 2010, was $25.3 million compared with income from operations for the three months ended June 26, 2009, of $21.6 million. Net income for the three months ended July 2, 2010, was $13.8 million, or $0.24 per diluted share, compared with net income for the three months ended June 26, 2009, of $13.3 million, or $0.23 per diluted share. Gary A. Corless, President and Chief Executive Officer, commented, “A discernable slowdown in utilization in the office-based physician market contributed to weaker-than-expected revenue in our fiscal year first quarter, which was slightly offset by successful execution of our key strategies. We have adjusted our consolidated revenue goal for fiscal year 2011 to a range of -1% to 1% for same day sales to reflect current physician market uncertainty. Our customers are benefitting from our solutions designed to help them improve clinical outcomes and practice more effectively and efficiently. We maintain strong fundamentals and competitive positions in both of our businesses, with increasing margins and solid cash flow generation, and we remain confident in our ability to achieve our earnings goal of $1.27 — $1.31 per diluted share.”




What is BEAT THE DART’S performance worth?